.jpeg)
2026-09-10 02:52:45
A multicenter Ib/II trial shows the azacitidine + venetoclax + ivosidenib triplet regimen achieves 95% ORR in newly diagnosed IDH1-mutant AML with manageable safety.
2026-09-09 07:04:37
Dacomitinib is a second-generation irreversible EGFR TKI for first-line treatment of metastatic NSCLC with EGFR exon 19 deletion or L858R mutation. This article details dosing, switching strategies, comparison with osimertinib, and adverse event management.
2026-09-09 06:37:44
Abemaciclib is a CDK4/6 inhibitor for hormone receptor-positive, HER2-negative breast cancer. This article explains its mechanism, synergy with endocrine therapy, efficacy differences between mono and combination, and precautions when switching from other CDK4/6 inhibitors.
2026-09-08 06:24:42
Fezolinetant is a non-hormonal oral medication for moderate to severe vasomotor symptoms of menopause. This article details standard dosing, missed dose management, and liver function monitoring.
2026-09-08 05:44:22
Lusutrombopag stimulates TPO receptors to raise platelet count, mainly for chronic liver disease patients before invasive procedures. This article details thrombosis risk, common side effects, and the US-approved regimen.
2026-09-08 05:39:33
Mirogabalin is used for neuropathic pain, but its analgesic effect is not immediate. This article explains dose titration, factors affecting onset, and the need for continuous observation.
2026-09-08 05:30:58
Cemiplimab is a PD-1 immune checkpoint inhibitor that blocks PD-1 from binding to PD-L1/PD-L2, releasing T-cell suppression and enabling immune attack on tumors. This article explains its mechanism and clinical indication screening.
2026-09-07 07:24:27
Tivozanib (FOTIVDA) is an oral targeted therapy for renal cell carcinoma, given on a 21-day-on, 7-day-off schedule. This article details standard dosing, hepatic impairment adjustment, hypertension monitoring, and side effect management.
2026-09-07 05:13:58
Does anagrelide worsen myelofibrosis in essential thrombocythemia (ET)? This article reviews clinical evidence, distinguishes drug effects from natural disease progression, and highlights monitoring strategies.
2026-09-07 05:08:46
Vorasidenib is an oral targeted therapy for glioma, taken continuously until disease progression or unacceptable toxicity. This article covers its dosing principles, liver monitoring, missed dose handling, and discontinuation rules.
2026-09-07 04:57:52
FDA approved Zanvastro intrathecal injection in September 2026 as the first disease-modifying drug for Alexander disease. This article covers its ASO mechanism, all-age indication, clinical trial efficacy, and safety guidelines.
2026-09-04 07:06:06
Pirfenidone (Esbriet) is an oral antifibrotic drug for idiopathic pulmonary fibrosis (IPF). This article details its stepwise dosing schedule, the necessity of taking with food, missed dose rules, and strategies for managing photosensitivity and gastrointestinal side effects.
